Literature DB >> 19891895

Dengue virus type 3 infection in traveler returning from west Africa.

Laetitia Ninove, Philippe Parola, Cécile Baronti, Xavier De Lamballerie, Philippe Gautret, Barbara Doudier, Rémi N Charrel.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19891895      PMCID: PMC2857216          DOI: 10.3201/eid1511.081736

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: GeoSentinel, the global surveillance program of the International Society of Travel Medicine, recently reported that returning travelers may serve as sentinels for local outbreaks of dengue fever in tropical areas to which it is endemic (). We investigated a case of dengue virus (DENV) type 3 (DENV-3) infection in a traveler returning to France from West Africa, which provided evidence for DENV-3 circulation in Côte d’Ivoire. A 53-year-old French expatriate living in Abidjan, the economic capital of Côte d’Ivoire, arrived in France on July 17, 2008, and was hospitalized 4 days later with fever of 40°C, headache, asthenia, anorexia, chills, diffuse arthralgia, and myalgia. Results of a physical examination were normal except for a diffuse nonpetechial macular rash and moderate hepatosplenomegaly. A tourniquet test was not performed. At admission, platelet count was 103 cells/mm3 and leukocyte count was 2,410 cells/mm3. Thin and thick blood smears and results of the immunochromatographic test (Binax NOW malaria tests; Binax, Portland, ME, USA) were negative. The patient recovered without sequelae and was discharged 6 days after admission. At admission, chikungunya virus–specific immunoglobulin (Ig) G and IgM were not detected by indirect immunofluorescence tests (). IgG, but not IgM, specific for DENV was detected by an immunochromatic test (Panbio Dengue Duo Cassette; Biotrin, Lyon, France) and confirmed by ELISA (PanBio dengue duo test). However, DENV RNA was demonstrated in serum by using 4 reverse-transcription–PCR (RT-PCR)–based assays: a positive result in a flavivirus universal assay (), a positive result in a DENV-1–4 real-time RT-PCR (), a positive result in a DENV-3–specific RT-PCR, and a negative result in a specific RT-PCR for DENV-1, -2, and -4 (). The concomitant finding of DENV RNA and IgG against DENV suggests the patient had dengue infection before this episode. DENV-3 viremia was confirmed by sequencing a 547-nt region of the envelope gene (GenBank accession no. FJ587232, nt 852–1398 referring to the H87 DENV-3 prototype strain). Our sequence aligned with homologous DENV-3 sequences retrieved from GenBank and used for phylogenetic analysis (Figure). Our patient, in whom classic dengue fever was diagnosed, was infected with a strain that belonged to genotype III most closely related to strains isolated in Singapore, Taiwan, Sri Lanka, India, and Saudi Arabia. Its closest relatives were the strain from Saudi Arabia isolated in 2004 and another strain claimed in ProMED by Japanese researchers to have been isolated in 2008 from a Japanese traveler returning from Côte d’Ivoire (). Therefore, this strain is likely to have originated in the Middle East, the Indian subcontinent, or Southeast Asia rather than in Central or South America.
Figure

Phylogenetic analysis of selected dengue virus type 3 (DENV-3) sequences. The main genotypes are indicated using roman numerals at the node of the lineage. Sequence identification is as follows: country of origin, strain name, year of isolation/detection. The sequence determined in our study is underlined and designated by an arrow. Phylogenetic studies were conducted by using MEGA version 2.1 (). Genetic distances were calculated with the Kimura 2-parameter method at the nucleotide level. Phylogenetic trees were constructed using the neighbor-joining method. The robustness of the nodes was tested by 500 bootstrap replications. The tree was rooted with DENV-1, DENV-2, and DENV-4 sequences. Scale bar indicates nucleotide substitutions per site.

Phylogenetic analysis of selected dengue virus type 3 (DENV-3) sequences. The main genotypes are indicated using roman numerals at the node of the lineage. Sequence identification is as follows: country of origin, strain name, year of isolation/detection. The sequence determined in our study is underlined and designated by an arrow. Phylogenetic studies were conducted by using MEGA version 2.1 (). Genetic distances were calculated with the Kimura 2-parameter method at the nucleotide level. Phylogenetic trees were constructed using the neighbor-joining method. The robustness of the nodes was tested by 500 bootstrap replications. The tree was rooted with DENV-1, DENV-2, and DENV-4 sequences. Scale bar indicates nucleotide substitutions per site. In Africa, most data on epidemic or endemic dengue activity originate in East Africa. Dengue fever was seldom reported in West Africa. In 2000, DENV-1 was isolated from a French soldier in Côte d’Ivoire (). More recently, an outbreak caused by DENV-2 occurred in Gabon in West Africa (). In this context, it is notable that DENV-3 strains recently caused unexpected outbreaks of dengue hemorrhagic fever in Sri Lanka, East Africa, and Latin America (). The case presented here demonstrates that epidemics may be undetected or unidentified until diagnosis is assessed in another country from a returning infected visitor, thus drawing attention to an unidentified potential epidemic situation. This situation can be unraveled by a clinician who considers geographic factors in the diagnostic workup and has access to and uses appropriate laboratory capacity to diagnose imported infections. At the time dengue was diagnosed in this patient, cases of yellow fever were reported in the same location of Côte d’Ivoire (Abidjan) (), illustrating concomitant circulation of 2 viruses in which dengue may have remained undetected in the absence of a laboratory-confirmed case in the traveler’s home country. Therefore, this case reinforces the utility of travelers as sentinels for infectious diseases as previously reported (). Our findings reiterate the need for technologic transfer of PCR-based direct diagnostics to reference centers in areas where emergence is likely. These efforts also should embrace serology and encourage close collaboration with world reference centers for confirmation and characterization ().
  10 in total

1.  MEGA2: molecular evolutionary genetics analysis software.

Authors:  S Kumar; K Tamura; I B Jakobsen; M Nei
Journal:  Bioinformatics       Date:  2001-12       Impact factor: 6.937

2.  A real-time RT-PCR method for the universal detection and identification of flaviviruses.

Authors:  G Moureau; S Temmam; J P Gonzalez; R N Charrel; G Grard; X de Lamballerie
Journal:  Vector Borne Zoonotic Dis       Date:  2007       Impact factor: 2.133

3.  Dengue in Africa: emergence of DENV-3, Côte d'Ivoire, 2008.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-03-13

4.  Isolation, characterization and geographic distribution of Caño Delgadito virus, a newly discovered South American hantavirus (family Bunyaviridae).

Authors:  C F Fulhorst; M C Monroe; R A Salas; G Duno; A Utrera; T G Ksiazek; S T Nichol; N M de Manzione; D Tovar; R B Tesh
Journal:  Virus Res       Date:  1997-10       Impact factor: 3.303

5.  Spectrum of disease and relation to place of exposure among ill returned travelers.

Authors:  David O Freedman; Leisa H Weld; Phyllis E Kozarsky; Tamara Fisk; Rachel Robins; Frank von Sonnenburg; Jay S Keystone; Prativa Pandey; Martin S Cetron
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

6.  Development and validation of real-time one-step reverse transcription-PCR for the detection and typing of dengue viruses.

Authors:  Isabelle Leparc-Goffart; Meili Baragatti; Sarah Temmam; Anne Tuiskunen; Gregory Moureau; Rémi Charrel; Xavier de Lamballerie
Journal:  J Clin Virol       Date:  2009-04-03       Impact factor: 3.168

7.  Isolation of a dengue type 1 virus from a soldier in West Africa (Côte d'Ivoire)

Authors:  J P Durand; L Vallée; J J de Pina; H Tolou
Journal:  Emerg Infect Dis       Date:  2000 Jan-Feb       Impact factor: 6.883

8.  Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006.

Authors:  Eli Schwartz; Leisa H Weld; Annelies Wilder-Smith; Frank von Sonnenburg; Jay S Keystone; Kevin C Kain; Joseph Torresi; David O Freedman
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

9.  Concurrent chikungunya and dengue virus infections during simultaneous outbreaks, Gabon, 2007.

Authors:  Eric M Leroy; Dieudoné Nkoghe; Benjamin Ollomo; Chimène Nze-Nkogue; Pierre Becquart; Gilda Grard; Xavier Pourrut; Rémi Charrel; Grégory Moureau; Angélique Ndjoyi-Mbiguino; Xavier De-Lamballerie
Journal:  Emerg Infect Dis       Date:  2009-04       Impact factor: 6.883

10.  Emergence and global spread of a dengue serotype 3, subtype III virus.

Authors:  William B Messer; Duane J Gubler; Eva Harris; Kamalanayani Sivananthan; Aravinda M de Silva
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

  10 in total
  11 in total

1.  Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development.

Authors:  Annelies Wilder-Smith; Eng-Eong Ooi; Subhash G Vasudevan; Duane J Gubler
Journal:  Curr Infect Dis Rep       Date:  2010-05       Impact factor: 3.725

2.  Acute arboviral infections in Guinea, West Africa, 2006.

Authors:  Emily S Jentes; Jaimie Robinson; Barbara W Johnson; Ibrahima Conde; Yosse Sakouvougui; Jennifer Iverson; Shanna Beecher; M Alpha Bah; Fousseny Diakite; Mamadi Coulibaly; Daniel G Bausch; Juliet Bryan
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

3.  First report of sylvatic DENV-2-associated dengue hemorrhagic fever in West Africa.

Authors:  Leticia Franco; Gustavo Palacios; José Antonio Martinez; Ana Vázquez; Nazir Savji; Fernando De Ory; María Paz Sanchez-Seco; Dolores Martín; W Ian Lipkin; Antonio Tenorio
Journal:  PLoS Negl Trop Dis       Date:  2011-08-02

4.  Dengue: challenges for policy makers and vaccine developers.

Authors:  Annelies Wilder-Smith; Paul Macary
Journal:  Curr Infect Dis Rep       Date:  2014-05       Impact factor: 3.725

5.  Dengue virus serotype 3 infection in traveler returning from West Africa to Germany.

Authors:  Isabella Eckerle; Annette Kapaun; Thomas Junghanss; Paul Schnitzler; Christian Drosten; Thomas Jänisch
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

6.  Dengue Virus Exported from Côte d'Ivoire to Japan, June 2017.

Authors:  Tetsuya Suzuki; Satoshi Kutsuna; Satoshi Taniguchi; Shigeru Tajima; Takahiro Maeki; Fumihiro Kato; Chang-Kweng Lim; Masayuki Saijo; Motoyuki Tsuboi; Kei Yamamoto; Shinichiro Morioka; Masahiro Ishikane; Kayoko Hayakawa; Yasuyuki Kato; Norio Ohmagari
Journal:  Emerg Infect Dis       Date:  2017-10-17       Impact factor: 6.883

7.  Surveys of Arboviruses Vectors in Four Cities Stretching Along a Railway Transect of Burkina Faso: Risk Transmission and Insecticide Susceptibility Status of Potential Vectors.

Authors:  Lissy Parfait Eric Ouattara; Ibrahim Sangaré; Moussa Namountougou; Aristide Hien; Ali Ouari; Dieudonné Diloma Soma; Daouda Kassié; Abdoulaye Diabaté; Olivier Gnankiné; Emmanuel Bonnet; Valéry Ridde; Maurice Adja Akré; Florence Fournet; Kounbobr Roch Dabiré
Journal:  Front Vet Sci       Date:  2019-05-28

8.  Surveillance of travel-associated diseases at two referral centres in Marseille, France: a 12-year survey.

Authors:  Karolina M Griffiths; Hélène Savini; Philippe Brouqui; Fabrice Simon; Philippe Parola; Philippe Gautret
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

9.  The incubation periods of Dengue viruses.

Authors:  Miranda Chan; Michael A Johansson
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Importation of dengue virus type 3 to Japan from Tanzania and Cote d'Ivoire.

Authors:  Meng Ling Moi; Tomohiko Takasaki; Akira Kotaki; Shigeru Tajima; Chang-Kweng Lim; Mitsuo Sakamoto; Hajime Iwagoe; Kenichiro Kobayashi; Ichiro Kurane
Journal:  Emerg Infect Dis       Date:  2010-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.